(Total Views: 493)
Posted On: 05/25/2025 8:32:20 AM
Post# of 154119
Thanks for this. Good info. I have some follow-up questions to your post.
(1) Do we know when the mouse study results from Einstein College of Medicine will be released?
(2) Also what are the two other cancer indications are that are being looked at (see quote below)?
(3) Do we know we know if any of the CRC patients in the basket trial received, in addition to Leronlimab, a checkpoint inhibitor, and do we know what their status is?
*In addition to CRC, CytoDyn is investigating the role for leronlimab in two other oncology indications via strategic and low-cost research and development opportunities, and in collaboration with several reputable institutions."
(1) Do we know when the mouse study results from Einstein College of Medicine will be released?
(2) Also what are the two other cancer indications are that are being looked at (see quote below)?
(3) Do we know we know if any of the CRC patients in the basket trial received, in addition to Leronlimab, a checkpoint inhibitor, and do we know what their status is?
*In addition to CRC, CytoDyn is investigating the role for leronlimab in two other oncology indications via strategic and low-cost research and development opportunities, and in collaboration with several reputable institutions."
(5)
(0)
